Allergan, Inc. - Product Pipeline Review - 2015

  • ID: 3169877
  • Company Profile
  • 83 pages
  • Global Markets Direct
  • Allergan plc
1 of 4
Allergan, Inc. - Product Pipeline Review - 2015

Summary

This, ‘Allergan, Inc. - Product Pipeline Review - 2015’, provides an overview of the Allergan, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Allergan, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Allergan, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Allergan, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Allergan, Inc.’s pipeline products

Reasons to buy

- Evaluate Allergan, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Allergan, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Allergan, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Allergan, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Allergan, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Allergan, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables
List of Figures
Allergan, Inc. Snapshot
Allergan, Inc. Overview
Key Information
Key Facts
Allergan, Inc. - Research and Development Overview
Key Therapeutic Areas
Allergan, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Allergan, Inc. - Pipeline Products Glance
Allergan, Inc. - Late Stage Pipeline Products
Filing rejected/Withdrawn Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Allergan, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Allergan, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Allergan, Inc. - Drug Profiles
dihydroergotamine mesylate
Product Description
Mechanism of Action
R&D Progress
Aczone X
Product Description
Mechanism of Action
R&D Progress
AGN-229666
Product Description
Mechanism of Action
R&D Progress
bimatoprost
Product Description
Mechanism of Action
R&D Progress
bimatoprost SR
Product Description
Mechanism of Action
R&D Progress
cyclosporine
Product Description
Mechanism of Action
R&D Progress
desmopressin acetate
Product Description
Mechanism of Action
R&D Progress
onabotulinumtoxin A
Product Description
Mechanism of Action
R&D Progress
oxymetazoline hydrochloride
Product Description
Mechanism of Action
R&D Progress
(bimatoprost + brimonidine tartrate)
Product Description
Mechanism of Action
R&D Progress
abicipar pegol
Product Description
Mechanism of Action
R&D Progress
AGN-195263
Product Description
Mechanism of Action
R&D Progress
beclomethasone dipropionate
Product Description
Mechanism of Action
R&D Progress
brimonidine tartrate implant
Product Description
Mechanism of Action
R&D Progress
lidocaine
Product Description
Mechanism of Action
R&D Progress
senrebotase
Product Description
Mechanism of Action
R&D Progress
AGN-223575
Product Description
Mechanism of Action
R&D Progress
AGN-151200
Product Description
Mechanism of Action
R&D Progress
Drug to Agonize D2/D3 Receptors for Parkinson's Disease
Product Description
Mechanism of Action
R&D Progress
Drug to Agonize GABA Receptor for Epilepsy
Product Description
Mechanism of Action
R&D Progress
Drug to Inhibit Tyrosine Kinase for AMD
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Glaucoma
Product Description
Mechanism of Action
R&D Progress
Neurotoxin Program
Product Description
Mechanism of Action
R&D Progress
Allergan, Inc. - Pipeline Analysis
Allergan, Inc. - Pipeline Products by Target
Allergan, Inc. - Pipeline Products by Route of Administration
Allergan, Inc. - Pipeline Products by Molecule Type
Allergan, Inc. - Pipeline Products by Mechanism of Action
Allergan, Inc. - Recent Pipeline Updates
Allergan, Inc. - Dormant Projects
Allergan, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
budesonide
dexamethasone
memantine hydrochloride
onabotulinumtoxin A
Allergan, Inc. - Company Statement
Allergan, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Allergan, Inc. - Key Manufacturing Facilities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Allergan, Inc., Key Information
Allergan, Inc., Key Facts
Allergan, Inc. - Pipeline by Indication, 2015
Allergan, Inc. - Pipeline by Stage of Development, 2015
Allergan, Inc. - Monotherapy Products in Pipeline, 2015
Allergan, Inc. - Combination Treatment Modalities in Pipeline, 2015
Allergan, Inc. - Partnered Products in Pipeline, 2015
Allergan, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
Allergan, Inc. - Out-Licensed Products in Pipeline, 2015
Allergan, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
Allergan, Inc. - Filing rejected/Withdrawn, 2015
Allergan, Inc. - Phase III, 2015
Allergan, Inc. - Phase II, 2015
Allergan, Inc. - Phase I, 2015
Allergan, Inc. - Preclinical, 2015
Allergan, Inc. - Discovery, 2015
Allergan, Inc. - Pipeline by Target, 2015
Allergan, Inc. - Pipeline by Route of Administration, 2015
Allergan, Inc. - Pipeline by Molecule Type, 2015
Allergan, Inc. - Pipeline Products by Mechanism of Action, 2015
Allergan, Inc. - Recent Pipeline Updates, 2015
Allergan, Inc. - Dormant Developmental Projects,2015
Allergan, Inc. - Discontinued Pipeline Products, 2015
Allergan, Inc., Subsidiaries
Allergan, Inc., Key Manufacturing Facilities

List of Figures
Allergan, Inc. - Pipeline by Top 10 Indication, 2015
Allergan, Inc. - Pipeline by Stage of Development, 2015
Allergan, Inc. - Monotherapy Products in Pipeline, 2015
Allergan, Inc. - Partnered Products in Pipeline, 2015
Allergan, Inc. - Pipeline by Top 10 Target, 2015
Allergan, Inc. - Pipeline by Top 10 Route of Administration, 2015
Allergan, Inc. - Pipeline by Top 10 Molecule Type, 2015
Allergan, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll